Paclitaxel - MGI GP

Drug Profile

Paclitaxel - MGI GP

Alternative Names: Paclimer microspheres

Latest Information Update: 28 Oct 2005

Price : $50

At a glance

  • Originator MGI GP
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP Inc
  • 30 Jun 2002 Paclimer® Microspheres technology is available for licensing (http://gulifordpharm.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top